Clinical trials: Goitre
Thyroid Eye Disease
A Study of TEPEZZA® Treatment in Participants With Thyroid Eye Disease
The main goal of this study is to learn how teprotumumab will be processed in the body (Pharmacokinetics) subcutaneously and whether it is safe and tolerable after administration into adult patients with thyroid eye disease.
- Trial name
- NCT06389578
- Testing
- Teprotumumab
- Where
- 3 sites in United States
- Volunteers
- 16 people
- Sponsor
- Amgen
Goiter
Subtotal Versus Total Thyroidectomy for Benign Goiter
The extent of thyroid resection in benign goiter is controversial. Potential advantages of TT over BST may include: one-stage removal of incidental thyroid cancer reported in up to 10% of operatively treated benign thyroid…
- Trial name
- NCT01273714
- Testing
- thyroid resection
- Where
- Poland
- Volunteers
- 8,006 people
- Sponsor
- Jagiellonian University
Thyroid Nodule, Thyroid Diseases
Fusion UltraSound Imaging Of the Thyroid GlaNd With I-124 PET. Evaluation of Nodule Allocation.
Regular thyroid diagnostics versus augmented thyroid work-up with additional I-124 PET/US fusion for metabolic-sonographic nodule allocation in patients with benign thyroid diseases
- Conditions
- Thyroid Nodule, Thyroid Diseases, Thyroid Goitre
- Trial name
- FUSION iENA (NCT03128255)
- Testing
- Assessment of already preacquired I-124 PET/US
- Where
- Germany
- Volunteers
- 70 people
- Sponsor
- Jena University Hospital
Thyroid Eye Disease
Efficacy and Safety of Lonigutamab in Subjects With Thyroid Eye Disease (TED)
Phase 1/2, multicenter, multiple dose clinical study designed to evaluate lonigutamab in subjects with TED.
- Trial name
- TED (NCT05683496)
- Testing
- lonigutamab
- Where
- 11 sites in United States, Australia
- Volunteers
- 31 people
- Sponsor
- ACELYRIN Inc.
Graves Ophthalmopathy
Bimatoprost as a Treatment for Graves' Orbitopathy
Testing whether Bimatoprost, a topical eye drop used for glaucoma, can be used to induce periorbital fat atrophy in patients with Graves' disease
- Trial name
- NCT03708627
- Testing
- Bimatoprost Ophthalmic
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Johns Hopkins University
Thyroid Eye Disease
Transconjunctival Versus Transcutaneous Betamethasone for Upper Eyelid Retraction in TED
This randomized controlled trial aims to compare the efficacy and safety of transconjunctival versus transcutaneous perilevator betamethasone injection in reducing upper eyelid retraction in patients with thyroid eye disease.
- Trial name
- NCT07866261
- Testing
- Betamethasone
- Volunteers
- 54 people
- Sponsor
- Assiut University
Thyroid Eye Disease
A Safety, Tolerability, and Efficacy Study of Veligrotug (VRDN 001) in Participants With Thyroid Eye Disease (TED)
The investigational drug, veligrotug (VRDN-001), is a monoclonal antibody that inhibits the activity of a cell surface receptor called insulin-like growth factor-1 receptor (IGF-1R).
- Trial name
- THRIVE (NCT05176639)
- Testing
- Veligrotug
- Where
- 53 sites in United States, Australia and 5 more
- Volunteers
- 113 people
- Sponsor
- Viridian Therapeutics, Inc.
Graves Disease
Study of BHV-1300 in Graves' Disease
The purpose of this study is to determine if BHV-1300 is a safe treatment in participants with Graves' Disease and to explore its effect on disease-specific biomarkers.
- Trial name
- NCT06980649
- Testing
- BHV-1300
- Where
- 18 sites in United States, Australia
- Volunteers
- 15 people
- Sponsor
- Biohaven Therapeutics Ltd.
Thyroid Eye Disease (TED)
Open-Label Extension Study of MHB018A in Subjects With Thyroid Eye Disease
This is a multicenter, open-label extension (OLE) study of MHB018A in subjects with moderate-to-severe TED.
- Trial name
- NCT07262476
- Testing
- MHB018A injection
- Where
- China
- Volunteers
- 258 people
- Sponsor
- Minghui Pharmaceutical (Hangzhou) Ltd
Graves Ophthalmopathy
A Randomized Clinical Trial of Intravenous Methylprednisolone With 2 Protocols in Patients With Graves Orbitopathy
Intravenous glucocorticoid (IVGC) is an accessible and effective therapy for Graves orbitopathy (GO); the 4.5-g weekly protocol is well studied, but many details of treatment protocols need to be clarified.
- Trial name
- NCT06510114
- Testing
- methylprednisolone(daily scheme), methylprednisolone(weekly scheme)
- Volunteers
- 150 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Graves' Disease
A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
This is a study to assess the efficacy, safety, and tolerability of IMVT-1402 in adult participants with Graves' disease (GD) who are hyperthyroid despite antithyroid drug (ATD) treatment.
- Trial name
- NCT06727604
- Testing
- IMVT-1402
- Where
- 134 sites in United States, Belgium and 8 more
- Volunteers
- 240 people
- Sponsor
- Immunovant Sciences GmbH
Graves Disease
Effective Iodide Therapy for Untreated Patients With Graves' Hyperthyroidism Avoiding Thionamide Drugs With Many Side Effects
As the drug treatment of Graves' hyperthyroidism, Plummer reported the effectiveness of excess iodide in 1923 and iodide was used as the therapy for Graves' hyperthyroidism starting from the 1930s.
- Trial name
- NCT04686006
- Testing
- Potassium Iodide
- Volunteers
- 504 people
- Sponsor
- Kyushu University
Graves' Ophthalmopathy
A Prospective, Randomized Trial of Intravenous Pulse Versus Sequential Steroid Therapy for Patients With Graves' Orbitopathy
This study was designed to compare the efficacy and safety of 4.5g iv MP administered in 12 weeks and 4 weeks.
- Trial name
- NCT01969019
- Testing
- methylprednisolone, prednisone
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Ruijin Hospital
Graves Disease
Effect of Lugol's Solution in the Patients With Graves' Disease
Context: Although some of endocrine surgeons administer Lugol's solution to decrease thyroid gland vascularity, there is still no agreement on its effectiveness.
- Trial name
- NCT00432146
- Testing
- lugol's solution
- Volunteers
- 36 people
- Sponsor
- Istanbul University
Goiter, Nodular, Total Thyroidectomy
Thyroid Cancer in Surgical Treated Multinodular Goiter
This study aims to investigate, based on existing knowledge, the incidence of occult thyroid carcinoma in a cohort of patients with MNG, providing new insights into the prevalence and characteristics of thyroid malignancies in…
- Conditions
- Goiter, Nodular, Total Thyroidectomy, Thyroid Cancer
- Trial name
- NCT06924242
- Testing
- total or partial thyroidectomy
- Where
- Italy
- Volunteers
- 223 people, healthy volunteers welcome
- Sponsor
- University of Foggia
Graves Disease
The Impact of Person Centred Care (PCC) in Grave's Disease
Mental fatigue (MF) is prevalent after Graves' disease (GD), which is the most common form of hyperthyroidism. We have reported that 38% of patients, compared to 11% of control subjects, suffer from MF more than 1 year after…
- Trial name
- NCT06309316
- Testing
- Person-centred care (PCC)
- Where
- Sweden
- Volunteers
- 220 people
- Sponsor
- Vastra Gotaland Region
Thyroid Eye Disease (TED)
Open-Label Extension Study of MHB018A in Patients With Thyroid Eye Disease
This is a multicenter, open-label extension (OLE) study of MHB018A in subjects with moderate-to-severe TED.
- Trial name
- NCT07620405
- Testing
- MHB018A injection
- Volunteers
- 219 people
- Sponsor
- Minghui Pharmaceutical (Hangzhou) Ltd
Thyroid Eye Disease
Evaluating the Efficacy and Safety of Teprotumumab N01 in Patients With Thyroid Eye Disease.
This is a prospective study designed to evaluate the efficacy and safety of Teprotumumab N01 in patients with Thyroid Eye Disease (TED).
- Trial name
- NCT07423013
- Testing
- [18F]AlF-NOTA-FAPI-04PET/CT, 5.0-T high-resolution MRI
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Peking University Third Hospital
Thyroid Eye Disease, Graves Orbitopathy
A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
The overall objective is to study the safety, pharmacokinetics and efficacy of linsitinib (a small molecule IGF-1R inhibitor) administered orally twice daily (BID) vs.
- Conditions
- Thyroid Eye Disease, Graves Orbitopathy, Endocrine System Diseases, Eye Diseases
- Trial name
- LIDS (NCT05276063)
- Testing
- Linsitinib
- Where
- 30 sites in United States, Canada and 3 more
- Volunteers
- 90 people
- Sponsor
- Sling Therapeutics, Inc.
Thyroid Eye Disease
A Study of IBI311 in Subjects With Active Thyroid Eye Disease
This is a multicenter, randomized, double-masked, placebo-controlled Phase II/III study in subjects with active thyroid eye disease.
- Trial name
- NCT05795621
- Testing
- IBI311
- Where
- China
- Volunteers
- 115 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.